Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026 - Research and Markets

Research and Markets
Posted on: 19 Aug 16

Research and Markets has announced the addition of the "Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016 - 2026" report to their offering.

The Non-Insulin Therapies for Diabetes: GLP-1 Agonists, DPP4 Inhibitors and SGLT2 Inhibitors, 2016-2026, report provides a comprehensive analysis of the current market landscape of these therapies and an informed opinion on how the market is likely to evolve over the next decade. The anti-diabetic drugs market broadly comprises of insulin and non-insulin therapies.

Non-insulin therapies are further classified under various categories based on their respective mechanisms of action. Of the different types of non-insulin therapies, GLP-1 agonists, DPP4 inhibitors and SGLT2 inhibitors have been the most popular in the last few years. As mentioned earlier, these therapeutic classes have captured the attention of a number of pharmaceutical companies and drug developers worldwide.

Several companies, including pharmaceutical giants, mid-sized players and start-ups, have come up with innovative technologies and novel formulations of these drug classes. Such advances have generated and sustained significant momentum in this segment of the industry.

Specifically, GLP-1 agonists, which have been researched for several years, have a rich pipeline of clinical and preclinical molecules. DPP4 inhibitors currently have a relatively larger market share; however, they are now giving way to other relatively newer and emerging classes such as SGLT2 inhibitors.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. GLP-1 Agonists

6. DPP4 Inhibitors / CD26 Antigen Antagonists

7. SGLT2 Inhibitors

8. Discontinued Molecules and Common Side Effects

9. Novel Non-Insulin Therapies for Diabetes

10. Market Forecast

11. Publication Analysis

12. KOL Analysis

13. Interview Transcripts

14. Conclusion

Companies Mentioned:

  • 3SBio
  • Aalborg Hospital
  • Aarhus University Hospital
  • Abbott Laboratories
  • ActivX Biosciences
  • Addex Therapeutics
  • Aegis Therapeutics
  • AIDS Clinical Trials Group
  • Ajinomoto
  • Alantos Pharmaceuticals
  • Albert Einstein College of Medicine
  • Alize Pharma
  • Alkem Labs
  • Alkermers
  • Allegheny Health Network
  • Allergan
  • Almirall
  • Alteogen
  • ALZA Pharmaceuticals
  • (400+ More)

For more information about this report visit

Related Topics: Immune Disorders Drugs, Endocrinology

View source version on

Business Wire

Last updated on: 19/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.